Latest from Mayo Clinic Cancer Center

PROfound Data Could Lead to First PARP Inhibitor Approval in mCRPC

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

Cytoreductive Nephrectomy in mRCC Paradigm Requires Careful Patient Selection

Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.

Dr. Vargas on Toxicity of SBRT Versus Standard Radiation in Prostate Cancer

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Frontline Setting in mRCC Continues to Evolve With Combo Regimens

Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon.

Dr. Ho on First-Line TKI Monotherapy in mRCC

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

Novel Agents Revolutionize Nonmetastatic CRPC Paradigm

Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.

Dr. Ho on Frontline Treatment Regimens in mRCC

Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Next Page >>

Inside Oncology

View more videos >>